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Key recommendations  
• The development of safe home-based, baked milk introduction plans based on 
individualised risk assessment could help many countries who may not be able to 
provide food challenge facilities due to limited hospital resources.   
 
• Further research is required to explore country-specific advice and compare different 
settings and clinical practices regarding the use of baked milk challenges.      
 
 
 
Introduction  
 In previous years, the cornerstone of the management of Cow’s Milk Allergy (CMA) was 
solely based on the strict avoidance of all cow’s milk (CM) and foods containing CM from 
the patient’s diet [1]. More recently, the importance of baked milk (BM) introduction into the 
diet of children with CMA has become well-recognised as a part of CMA management. 
Current research suggests that 75% of children become tolerant to baked/heated forms of CM 
such as muffin and waffles before they become tolerant to pure/uncooked forms of CM [2]. It 
has been demonstrated that children who tolerated BM were 28 times more likely to become 
tolerant to CM compared to those children who were not able to tolerate these foods [3].  
Further, the ingestion and incorporation of BM containing foods into the children’s diet 
seemed to accelerate the resolution of CMA without any adverse effects on children’s 
growth, intestinal permeability, or the severity of coexisting diseases such as asthma, atopic 
dermatitis and allergic rhinitis [4].  Identification of CMA children who are able to tolerate 
BM in a variety of forms can also contribute to a liberalised diet that improves the quality of 
life of patients. This strategy may additionally help to avoid an unnecessary restriction of BM 
containing foods or to prevent a severe reaction that could be provoked with the uncooked 
milk; children reactive to BM appear to be at higher risk for systemic reaction than those 
children that tolerate BM but still remain allergic to uncooked milk [2, 5].    
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In the UK, CM is one of the most common foods responsible for a fatal anaphylactic reaction 
in children less than 16 years of age, and food allergy is the main cause of a fatal 
anaphylactic reaction outside the hospital setting [6, 7].  It is difficult to estimate how many 
people die each year from food anaphylaxis and to confirm the trigger that caused these 
tragedies. We are aware of a fatal anaphylactic reaction in a child following eating a milk 
product outside the healthcare setting in the UK, two years ago. This further emphasises that 
the decision to challenge at home should not be taken lightly and that there is a risk of severe 
reactions, even anaphylaxis. 
 
At the time of completion of this survey few guidelines were available on BM introduction. 
In the UK, the MAP Milk Allergy guidelines provide information on the initial diagnosis and 
the management of mild to moderate non-IgE-mediated CMA in primary care using a milk 
ladder (ML) [8]. The British Society of Allergy and Clinical Immunology (BSACI) guidance 
for home introduction of BM containing foods in IgE-mediated CMA was first published at 
the end of the survey period [9]. However, there are no studies indicating which patients are 
optimal candidates for home introduction of BM.  Additionally, there is no universal 
agreement for the criteria used to classify the severity of allergy symptoms as mild, moderate 
or severe and no reliable biomarkers that can be used to indicate the safety of home 
introduction of milk containing foods. This study was conducted to explore what guidelines 
and approaches are currently being used by healthcare professionals (HCPs) across the world 
and what their experiences have been in introducing a full portion of a BM product as a 
challenge (BMC) over 1 day or as a more gradual introduction over a number of days/weeks 
before moving on to other baked milk foods, as per a ML approach.  
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Methods 
A web-based global survey was conducted to capture the views of HCPs using a BMC and/or 
a ML. An electronic questionnaire (see additional file) was developed consisting of 23 short 
questions which could be completed within approximately 15 minutes. The main sections of 
the questionnaire were:  
• Characteristics of HCPs including: professional background and level of allergy 
training, practice setting (private/hospital-primary/secondary/tertiary care) and 
amount of time spent consulting patients with food allergies, percentage of 
respondents from various countries and guidelines that HCPs considered before they 
made the decision about the setting of BMC/ML. 
• Were these challenges used and where were these challenges performed? 
• What was the HCPs’ opinion on the safety of home-BMC and ML? 
• What was the HCPs’ opinion on parental anxiety in BMC/ML process?   
• What symptoms were observed?   
 An initial pilot testing of the survey was carried out on a group of HCPs practising in 
different parts of the world to ensure the clarity of questions. Ethical permission of the study 
was provided by the University of Portsmouth Science Faculty Ethics Committee. HCPs 
involved in the diagnosis and management of CMA were invited to complete the online 
questionnaire. The participants were identified through international professional 
organisations (ᵃFAISG, ᵃᵃBSACI, ᵇAAAAI, ᵇᵇADA, ᶜINDANA, ᶜᶜALLSA, ᵈASCIA, ᵈᵈDAA, 
ᵉWAO).  
 
 
ᵃ Food Allergy and Intolerance Specialist Group of British Dietetic Association; ᵃᵃBritish Society for Allergy and Clinical Immunology; 
ᵇ American Academy of Asthma Allergy and Immunology; ᵇᵇ American Dietetic Association ;  ᶜ International Network for Diet and Nutrition 
in Allergy; ᶜᶜAllergy Society of South Africa; ᵈDietitians Association of Australia ;ᵈᵈ Australasian Society of Clinical Immunology and 
Allergy;ᵉ Word Allergy Organisation  
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A reminder email was sent 4 weeks later. The survey was carried out between January and 
April 2014. The Bristol Online Survey was used to analyse and describe the results. 
Descriptive statistics were used to summarise data using a combination of tabulation and 
graphical description. Further statistical analysis data were entered and analysed using IBM 
SPSS Statistics for Windows version 22.0. Pearson’s chi-square test was used:  a) to 
determine whether or not there was a statistically significant relationship  between the use of 
BMC and ML; b) to test whether or not a statistically significant association exists between 
the settings (clinical/home) regarding where to perform BMC/ML and  the types of CMA 
(IgE and non-IgE-mediated CMA).  A P value less than 0.05 was considered statistically 
significant.  
 
Results 
Characteristics of HCPs study participants 
 A total of 114 HCPs completed the questionnaire and provided data on their clinical practice 
regarding using either a BMC and/or a ML in both IgE and non-IgE-mediated CMA. The 
largest groups of respondents were dietitians with an interest in allergy [52(46%)] followed 
by paediatric allergists/immunologists [46(40%)]. The majority of participants [106(93%)] 
indicated that they were involved in the management of IgE and non-IgE-mediated CMA in 
infancy and childhood. Most of the participants were based in the UK [56(49%)], followed by 
the US [20(18%)] and were practicing in secondary care/hospital [52(39%)] followed by 
tertiary care/specialist centre [42(37%)]. HCPs reported that they based their decision 
regarding BM introduction on an individualised clinical assessment (medical history, SPTs, 
laboratory tests) and national/regional guidelines. Demographic features of all respondents 
are shown in Table 1.      
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Settings (hospital/home) of BMC and ML in children with CMA based on HCPs reports  
IgE-mediated CMA  
Ninety-three (82%) HCPs indicated that they used BMC to identify patients able to tolerate 
BM products before tolerating uncooked milk. Fifty two (56%) respondents stated that they 
conducted these challenges in a clinical setting, 8(9.0%) in a home-based setting and 
33(35%) reported using both settings.  For ML, 68(60%) HCPs stated that they used this 
approach to determine the development of tolerance to BM in different forms. Nineteen 
(28%) respondents reported that they used the ML approach in a clinical setting, 22(32%) in a 
home setting and 27(40%) in both settings.  
 
Non-IgE-mediated CMA  
Eighty-six (75%) of the respondents stated that they used BMC to determine the development 
of tolerance to BM. Eight (9%) HCPs reported that they challenged their patients in a clinical 
setting, 51(59%) used home–based challenges and 27(31%) reported using both settings. In 
terms of using the ladder approach (ML), 77(68%) HCPs reported that they used the ML to 
identify children able to tolerate a range of BM containing foods. Three (4%) HCPs reported 
that they used ML in a clinical setting, 56(73%) at home and 18(23%) reported using both 
settings.  Choice of challenge setting (clinic/home) was statistically significant (p<.001) 
associated with the type of CMA (IgE/non-IgE-mediated). A greater number [52(56%)] of 
hospital-based BMC responses were indicated in IgE-mediated CMA, with a larger number 
[51(59%)] of home-based BMC in non-IgE-mediated CMA. The decision about where to 
perform milk ladder challenges (hospital/home) was also statistically significantly (p<.001) 
associated with the types of CMA.  A considerable number of respondents used ML 
challenges/introductions at home in both IgE [22(32%)] and non-IgE-mediated CMA 
[56(73%)].   
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However, choosing the safest challenge setting remains a difficult decision that concerns not 
only HCPs, but also carers. The majority of HCPs [71(62%)] considered the home/outside the 
clinical setting as a safe place to conduct both BMC and ML in non-IgE-mediated CMA 
because there is no risk of severe reactions, with an exception in the case of severe forms of 
non-IgE-mediated diseases, such as Food Protein Induced Enterocolitis Syndrome (FPIES). 
The most commonly reported symptoms experienced by the patients were reported as atopic 
eczema and abdominal pain in both hospital and home-based challenges (Table 2). In terms 
of IgE-mediated CMA, 30(26%) respondents stated that the home environment was a safe 
place to conduct either approach whereas 65(57%) HCPs considered the home/outside the 
clinical setting as a non-safe place to conduct both BMC and ML, due to potential severe 
symptoms (Table 2).  
 
Discussion 
The results from this survey indicate that 32(28%) HCPs reported anaphylaxis in clinic-based 
BMC and 9(8%) respondents in clinic – based ML challenges, but none at home. This finding 
is consistent with previous studies, reporting that some children develop anaphylaxis after 
ingestion of baked milk containing foods such as a muffin/pizza in hospital [3, 10]. Mehr and 
colleagues identified clinical predictors of reacting to baked cow’s milk [10]. These included 
children with; asthma requiring preventer therapy, IgE-mediated clinical reactions to more 
than 3 foods, a prior history of anaphylaxis to cow’s milk and highly atopic children. They 
indicated that such children should undergo BMCs in hospital. This study by Mehr involved 
challenges with increasing amounts of BM being introduced over a number of hours over the 
same day and 27% of children did not pass these oral food challenges [10]. This shows that 
baked milk challenges carry a risk in those with IgE-mediated CMA, and in a number of 
children with non-IgE-mediated CMA. The findings from this survey highlight that there 
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were no cases of reported anaphylaxis at home during baked milk challenges. This could be 
due to successful individual risk assessment and choosing an appropriate setting accordingly. 
This is supported by the fact that there were more IgE-mediated reactions associated with 
baked milk challenges in the clinical setting compared with the home. 
 
Healthcare systems differ between countries and many European countries may not be able to 
provide food challenge facilities for all food allergic patients as considerable hospital 
resources are required [11]. Such challenges are time consuming with long waiting lists, a 
major problem in many allergy clinics. For practical reasons, allergy services attempt to 
address this issue by suggesting initial introduction of BM containing foods at home based on 
a clinical assessment. The findings from our survey indicate that the decision regarding the 
location of challenges in the majority of cases is based on an individualised clinical 
assessment looking for such specific parameters as: sIgE levels, skin prick tests, severity of 
previous symptoms, severe forms of non-IgE-mediated CMA such as FPIES or mixed IgE 
and non-IgE-mediated CMA. Parents’ and children’s anxiety is another factor that is 
considered by HCPs. A considerable number of HCPs reported that the families were anxious 
when BMC [46(36%)] or ML [41(36%)] were conducted either at home or in a clinical 
setting. A better understanding of parents’ perceptions regarding the use of BM forms would 
be helpful for HCPs to provide optimal care to children during introduction of BM containing 
foods.         
 
 This survey has clearly highlighted the lack of international guidance on challenge/gradual 
introduction of baked cow’s milk in a matrix (ML). The World Allergy Organization, 
European Academy of Allergy and Clinical Immunology and PRACTALL consensus report 
recommends milk challenges in a safe, well-equipped environment that is supervised by a 
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medical team and have published guidelines for milk oral food challenges but these 
guidelines do not focus on BMC or a ML process [1, 11, 12].  However, since the survey was 
completed the BSACI guidelines were published and data from UK respondents may now be 
different.  
   
In conclusion, our findings suggest that there are a number of inconsistencies between the use 
of BMC versus ML. We suggest that a larger sample size with a sampling frame inclusive of 
more countries and clinicians from tertiary, secondary and primary care should be conducted. 
There is a clear need for universal guidance, taking into account country- specific needs, on 
the safe introduction of baked milk products.  
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Table 1: Demographic characteristics of respondents    
Characteristics  Options Respondents 
(n=114) (%)   
 Professional 
background   
Dietitians 
Paediatric Allergist/Allergist/Immunologist 
Paediatrician with Allergy interest   
Other* 
52(46) 
32(28) 
14(12) 
16(14) 
 Practice Settings  Secondary Care/Hospital 
Tertiary Care/Specialist Centre 
Private Practice 
Primary Care/Community 
Other** 
 
52(39) 
42(37) 
19(14) 
16(12) 
    4(3) 
Allergy training Work-based experiential learning  
Speciality in Allergology/Immunology 
Postgraduate  Dip in Allergy 
MSc in Allergy 
PhD in Allergy 
Postgraduate Cert in Allergy 
Other*** 
50(38) 
36(27) 
10(8) 
  8(6) 
  8(6) 
  4(3)   
16(12) 
  Food allergy  weekly 
workload  
>50% 
<50% 
62 (54) 
52 (46) 
CMA patients seen 
by HCPs  
Infants/children 
Adults 
106(93) 
 37 (32 ) 
Participated 
countries  
United Kingdom  
North & South America 
Oceania, Africa, Asia 
Europe  
56( 49) 
24 (21) 
20(18( 
14(12) 
Guidelines for 
hospital -BMC 
Medical history/SPT/IgE 
Regional/National 
International 
Hospital policy 
40(35) 
24(21) 
12(11) 
  9(8) 
Guidelines for home-
BMC 
Medical history/SPT/IgE 
Regional/National 
International 
Hospital policy 
39(34) 
26(23) 
  6(5) 
  5(4) 
Guidelines for 
hospital-ML 
Medical history/SPT/IgE 
Regional/National 
International 
Hospital policy 
24(21) 
26(23) 
  4(4) 
  3(3) 
Guidelines for home-
ML 
Medical history/SPT/IgE 
Regional/National 
International 
Hospital policy 
22(19) 
30(26) 
  4(3) 
  4(3)   
*Other:  Pharmacists, Nutritionists, Allergy Paediatric Nurses, Physicians, General Practitioners  
**Other: Ministry of Health & Welfare, Research 
***Other: Research, Continued Professional Development (CPD) & Continuing Medical Education (CME) resources, allergy training, 
completed allergy modules       
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  Table 2:  Summary of the most frequently reported symptoms by the HCPs for BMC & ML   
 
Clinical Symptoms                     IgE-mediated CMA  
  Clinical setting *N (%)           Home *N (%) 
BMC                ML                 BMC           ML 
Urticaria  
Vomiting  
Angioedema 
Runny nose & eyes 
Nausea  
Wheezing  
Diarrhoea 
Anaphylaxis  
68 (60)         34(30)            32(28)          25(22) 
55 (48)         24(21)            33(29)          22(19) 
49 (43)         23(20)            10(9)              9(8) 
49 (43)         19(17)            13(9)            12(11)  
48 (42)     20(18)            16(14)          22(19) 
39 (34)         15( 13)             3(2)              4(3) 
34 (30)         17(15)            42(37)          35(31) 
32 (28)           9(8.0)                  -                    -  
 
                Non-IgE-mediated CMA 
 Clinical setting *N (%)         Home *N (%) 
  BMC           ML              BMC                   ML   
Atopic eczema 
Abdominal pain  
Diarrhoea 
Gastro-oesoph. reflux 
Colic 
Food aversion 
Constipation 
 
20(18)         8(7)            43(38)                37(32) 
18(16)         4(3)            41(36)                32(28)   
15(13)         6(5)            37(32)                35(31) 
12(11)         4(3)            32(28)                30(26)                         
  7(6)            2(1)            22(19)                17(15) 
  6(5)            4(3)            17(15)                12(10) 
  5(4)            4(3)            43(38)                29(25) 
 
  
 
*N: number of responses 
  
